Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- GIII +14.5%, CVGW +10.4%, SAIC +5.8%, PATH +4.5% (also authorizes new $500 mln share repurchase program), BASE +4.4%, GME +3% (also continues to evaluate portfolio of assets), KFY +2.3%, AGX +1.9%, DOOO +1.2%
Other news:
- CBAY +21.1% (Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis)
- NRIX +13.4% (enters multi-target strategic collaboration agreement with Seagen (SGEN))
- KOD +8.1% (reports new one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial)
- WRK +6.7% (WestRock and Smurfit Kappa (SMFKY) in discussions regarding key terms of potential combination)
- CRVS +4.3% (confirms planned initiation of CPI-818 phase 3 trial)
- HCI +3.9% (provides update on impact from Hurricane Idalia)
- BKCC +3.4% (BKCC and TCPC to merge into subsidiary of TCPC)
- SMR +3.1% (Chubu Electric aiming to invest in SMR according to Bloomberg)
- FLR +2.3% (settles with SEC will pay $14.5 mln fine)
- ALNY +1.5% (reports positive topline results from KARDIA-1 Phase 2 dose-ranging study of zilebesiran an investigational RNAi therapeutic in development to treat hypertension in patients at high cardiovascular risk)
- EQR +1.3% (provides operating update)
- BTAI +1.1% (FDA has scheduled a Type C meeting for November 8 2023 to discuss the Company's BXCL501 SERENITY III clinical development program)
- NSTG +1% (discloses patent court update in 10x Genomics (TXG) case)
Analyst comments:
- MTN +3.3% (upgraded to Buy from Hold at Truist)
- MCD +0.9% (upgraded to Overweight from Equal Weight at Wells Fargo)